CUE BIOPHARMA INC
Cue BioPharma (ticker: CUE) is a clinical-stage biotechnology company developing targeted immune activators designed to engage a patient’s own immune system against cancer. Its technology seeks to direct and amplify antigen-specific T cell responses, with lead candidates in oncology indications. As an early-stage biopharma with a market capitalisation around $63.4m, Cue is research- and development‑intensive and typically reports limited or no commercial revenue. Key points for investors include the binary nature of clinical trial readouts, dependence on successful regulatory interactions, and the potential need for additional financing which can dilute shareholders. The share price can be volatile and sensitive to scientific data, partnership news and funding updates. For many investors, Cue may be better suited to a small, speculative part of a diversified portfolio. This is educational information only and not personalised advice — clinical outcomes are uncertain and past behaviour is not a reliable guide to future performance.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying CUE Biopharma's stock, with a target price of $6.
Financial Health
CUE Biopharma is performing well with solid revenue and cash flow, indicating good financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Why You’ll Want to Watch This Stock
Trial Readouts Matter
Clinical data are primary value drivers for Cue; positive or negative results can move the stock sharply, though outcomes are uncertain.
Binary Clinical Risk
As an early-stage biotech, Cue faces high binary risk around trial outcomes and regulatory decisions; potential reward comes with elevated volatility.
Partnerships & Funding
Licensing deals or successful financing can de‑risk development and extend runway, but funding needs may also dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.